Psilocybin Information
What Is Psilocybin Actually Studied For?
The evidence is strongest regarding Depression
Depression
Depression. This is where the evidence is strongest.
More on Depression Research
A 2024 meta-analysis pooled 8 randomized controlled trials (524 adults) and found a large reduction in depression symptoms with psilocybin-assisted therapy compared to control conditions [1]. A separate, ongoing “living” meta-analysis (drawing on 15 trials and over 800 participants) found a similarly large effect [2]. To put “large effect” in plain terms: the improvement wasn’t small or marginal — it was substantial compared to what we typically see with standard antidepressants in trials. That said, it’s worth being honest about the caveats: most of these trials are still fairly small, many have design limitations (like difficulty truly blinding participants to whether they got psilocybin or a placebo), and a more recent 2025 analysis found that placebo/control groups in psilocybin trials tend to do worse than control groups in SSRI or esketamine trials — which complicates how we interpret the size of the effect [3]. In short: promising, but the field is still young, and I’m not going to oversell it to you.
Depression and anxiety related to serious illness.
People facing cancer or other life-threatening diagnoses who develop significant depression or anxiety as a result.
More on Depression and anxiety related to serious illness.
This is one of the more well-studied applications — people facing cancer or other life-threatening diagnoses who develop significant depression or anxiety as a result. A 2020 meta-analysis pooled multiple trials in this population and found significant improvements in both depression and anxiety scores compared to control groups [4].
Substance use
Alcohol and Tobacco, mainly
More on Substance Abuse
A 2023 systematic review looked at psilocybin-assisted therapy for addiction and found encouraging reductions in heavy drinking days and smoking cessation rates in the small number of trials that exist [5]. A separate 2025 systematic review found similar patterns, with the strongest (though still early) evidence for alcohol use disorder and tobacco use disorder, and more mixed, preliminary findings for opioid and cannabis use [6].
Other areas
Early and Emerging, not yet well-established.
More on Other Areas that are early and emergine
Smaller studies and case reports have looked at psilocybin for OCD, PTSD, eating disorders, and existential distress more broadly. I want to be upfront that the evidence here is much thinner than for depression — often just a handful of small trials or open-label studies, not the kind of large randomized, controlled research we have for depression. Promising, but not proven yet.
The Honest Summary
Psilocybin-assisted therapy has real, peer-reviewed evidence behind it
”more>”
Psilocybin-assisted therapy has real, peer-reviewed evidence behind it — particularly for depression and for depression/anxiety tied to serious illness — but it is not a guaranteed fix, it is not FDA-approved for any condition as of this writing, and the field is still actively learning who benefits most and why.
Anyone telling you it’s a miracle cure isn’t being straight with you, and neither would I be.
Bibliography
This is not an exhaustive literature review, just a representative sample of the strongest, most recent meta-analyses and systematic reviews. Research in this space moves quickly, so I’d treat this list as a snapshot rather than any kind of authority.
Bibliography (snapshot)
Bibliography
- Fang, S., Yang, X., & Zhang, W. (2024). Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Psychiatry, 15, 1359088.
- Singleton, S. P., Sevchik, B. L., Lahey, A., Cuijpers, P., Harrer, M., Jones, M. T., Nayak, S. M., Strain, E. C., Vandekar, S. N., Dworkin, R. H., Scott, J. C., & Satterthwaite, T. D. (2025). Psilocybin treatment for symptoms of depression: A living systematic review, meta-analysis, and data resource. medRxiv.
- Hieronymus, F., López, E., Werin Sjögren, H., & Lundberg, J. (2025). Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: A meta-analysis. JAMA Network Open, 8(7), e2524119.
- Vargas, A. S., Luís, Â., Barroso, M., Gallardo, E., & Pereira, L. (2020). Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases — A systematic review and meta-analysis of clinical trials. Biomedicines, 8(9), 331.
- van der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., & Batalla, A. (2023). Therapeutic effect of psilocybin in addiction: A systematic review. Frontiers in Psychiatry, 14, 1134454.
- Meshkat, S., Malik, G., Zeifman, R. J., Swainson, J., Balachandra, K., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A., Vermetten, E., Mayo, L. M., Tanguay, R., Jetly, R., & Bhat, V. (2025). Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review. Neuroscience & Biobehavioral Reviews, 173.
This is not an exhaustive literature review, just a representative sample of the strongest, most recent meta-analyses and systematic reviews. Research in this space moves quickly, so I’d treat this list as a snapshot rather than any kind of authority.
Anyone telling you it’s a miracle cure isn’t being straight with you, and neither would I be.
The honest summary: psilocybin-assisted therapy has real, peer-reviewed evidence behind it — particularly for depression and for depression/anxiety tied to serious illness — but it is not a guaranteed fix, it is not FDA-approved for any condition as of this writing, and the field is still actively learning who benefits most and why. Anyone telling you it’s a miracle cure isn’t being straight with you, and neither would I be.
Rooted in science. Open to wonder.
I believe there is a way to hold both rigor and mystery.
Natural Medicine experiences can touch places that are difficult to explain. They can bring us into contact with emotion, memory, embodiment, relationship, meaning, awe, and sometimes experiences that leave us with more questions than answers. I don't think we need to explain those experiences away, and I don't think we need to turn them into certainty.
- There is room here for neuroscience and mystery.
- For evidence and lived experience.
- For mental health and spirituality.
- For curiosity without certainty.
- For awe without needing to name exactly what we have encountered.
Most importantly, there is room for the person.
My role is not to tell you what your experience means or who you should become because of it. It is to help create the conditions for you to explore your experience safely, with thoughtful preparation, appropriate boundaries, genuine curiosity, and respect for your own capacity to make meaning.
I am interested in what these experiences might help us develop: greater capacity to meet difficult emotions, resilience in the face of uncertainty, a deeper relationship with ourselves and others, and perhaps a little more room for acceptance, wonder, compassion and possibility.
Some things may become clearer. Some things may remain mysterious.
I think both are okay.
I believe we can be deeply rooted in science without closing ourselves to wonder.
Rooted in science. Open to wonder.
The Anam Arbor Colorado Philosophy
